Both in Pharmaceuticals
Niagen Bioscience vs Upstream Bio
Over the past year NAGE returned −67.4% and UPB returned −86.5%; their daily moves had a correlation of 0.15.
NAGE −67.4% UPB −86.5%Growth of $1, one year, split-adjusted
| Metric | NAGE | UPB |
|---|---|---|
| Price | $2.36 | $3.39 |
| Market cap | $186.7M | $185.7M |
| Today | −1.67% | +1.19% |
| 1 month | −11.9% | −30.1% |
| 6 months | −51.0% | −62.8% |
| Year to date | −62.9% | −87.5% |
| 1 year | −68.7% | −86.9% |
| Revenue growth (YoY) | −4.3% | −17.5% |
| Gross margin | 64.8% | 100.0% |
| Net margin | 3.2% | −5136.1% |
| P/E (TTM) | 11.7× | — |
| Price / sales | 1.4× | 58.8× |
| Net cash | $66.7M | $261.3M |
| Dividend yield | — | — |
| Volatility (60d) | 37.2% | 82.1% |
| Short % of float | 8.0% | 13.2% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).